|1.||Hashimoto, Kenji: 17 articles (01/2015 - 03/2007)|
|2.||Iwata, Nakao: 8 articles (01/2014 - 01/2006)|
|3.||Higuchi, Hisashi: 8 articles (04/2010 - 01/2002)|
|4.||Kishi, Taro: 7 articles (01/2014 - 01/2009)|
|5.||Nakamura, Jun: 7 articles (01/2014 - 01/2002)|
|6.||Yoshida, Keizo: 7 articles (06/2008 - 01/2002)|
|7.||Takahashi, Hitoshi: 7 articles (06/2008 - 01/2002)|
|8.||Shimizu, Tetsuo: 7 articles (01/2006 - 01/2002)|
|9.||Silver, Henry: 6 articles (05/2015 - 10/2002)|
|10.||Yoshimura, Reiji: 6 articles (01/2014 - 01/2002)|
|1.||Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive)
01/01/2002 - "Fluvoxamine (50 to 300 mg/day) for 8 to 16 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) [measured across multiple assessment scales] compared with placebo in a well controlled trial in paediatric patients (n = 120) or from baseline in noncomparative trials in adolescent (n = 20) or paediatric (n = 16) patients. "
01/01/2001 - "Fluvoxamine (50 to 300 mg/day) for 8 to 16 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) [measured across multiple assessment scales] compared with placebo in a well controlled trial in paediatric patients (n = 120) or from baseline in noncomparative trials in adolescent (n = 20) or paediatric (n = 16) patients. "
10/01/2000 - "fluvoxamine 100 to 300 mg/day for 6 to 10 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) compared with placebo. "
01/01/1998 - "We investigated whether the combination of multi-modal behaviour therapy (BT) with fluvoxamine is superior to BT and placebo in the acute treatment of severely ill in-patients with obsessive-compulsive disorder (OCD). "
08/01/1987 - "Fluvoxamine appears effective in treating severe obsessive-compulsive disorder."
|2.||Anxiety Disorders (Anxiety Disorder)
09/01/1999 - "Although preliminary, our findings suggest that fluvoxamine is effective in treating outpatients with major depression with comorbid anxiety disorder, having a significant effect on both depression and anxiety symptoms. "
10/01/2000 - "On the basis of current treatment guidelines, fluvoxamine, like other SSRIs, is recommended as first-line treatment for a number of anxiety disorders. "
09/01/1999 - "Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders."
04/01/2004 - "Both physician and patient-rated scales indicate that fluvoxamine CR is effective and safe for the treatment of generalized social anxiety disorder."
02/01/2004 - "In summary, fluvoxamine CR is an efficacious, safe, and well-tolerated treatment of generalized social anxiety disorder."
|3.||Panic Disorder (Panic Attack)
07/01/1998 - "Fluvoxamine was not significantly superior to placebo with regard to the main outcome criterion, i.e., the reduction in the number of panic attacks, but it was significantly more effective with regard to the diminution in the number of limited panic attacks and showed a tendency to significance in respect of GAS and CGI. "
10/01/1993 - "The results indicate that: (1) the administration of fluvoxamine, as compared with placebo, led to a significant reduction in the number of panic attacks. "
10/01/1993 - "Although both groups improved on all measures, the fluvoxamine group experienced significantly less frequent major panic attacks from the third week on and significantly lower ratings on anxiety, depression, and disability from the sixth week on. "
01/01/1996 - "The efficacy of fluvoxamine in the treatment of panic disorder complicated by depression was investigated in an 8-week, single-group, open-label, flexible-dose trial. "
08/05/2001 - "Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients."
|4.||Schizophrenia (Dementia Praecox)
10/01/2010 - "Fluvoxamine improved cognitive impairments in a patient with schizophrenia."
12/01/2013 - "Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials."
10/01/2013 - "Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center."
10/01/2012 - "This study suggests no major benefit of fluvoxamine adjunctive therapy to improve cognitive impairments in patients with schizophrenia. "
10/01/2012 - "A randomized, double-blind, placebo-controlled, parallel trial of fluvoxamine adjunctive therapy in patients with schizophrenia was performed. "
|5.||Post-Traumatic Stress Disorders (PTSD)
06/01/2000 - "After 10 weeks of fluvoxamine treatment (100-300 mg/day), patients' PTSD, depression, and physiologic reactivity improved significantly. "
01/01/1996 - "Fluvoxamine was effective for treating the core intrusion, avoidance, and arousal symptoms of PTSD. "
01/01/2002 - "This study was designed to investigate the efficacy of the antidepressant fluvoxamine in the treatment of combat-related post-traumatic stress disorder (PTSD). "
07/01/2001 - "This study assesses the efficacy of fluvoxamine treatment on different domains of subjective sleep quality in Vietnam combat veterans with chronic posttraumatic stress disorder (PTSD). "
01/01/2002 - "Controlled studies of fluvoxamine in the treatment of PTSD are warranted."
|1.||Serotonin (5 Hydroxytryptamine)
|2.||sigma-1 receptor (receptor 1, sigma)
|7.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
|1.||Drug Therapy (Chemotherapy)